Begin with the product’s intended purpose, composition, presentation and claims. In Pakistan, the resulting classification determines which rules, permissions, evidence and submission channel apply.
Classify the product
Document the proposed claims, use, composition and presentation. Determine whether the product follows the pharmaceutical, medical device, alternative medicine, health product or another applicable route. Seek product-specific clarification when a borderline classification would change the dossier or permitted claims.
- Output: Classification rationale and applicable legal instruments.
Map establishment permissions
Identify the legal applicant, manufacturer, importers and distribution activities. Check the authorization scope for the relevant site and product category, including any provincial requirements that apply to the intended activity.
- Output: Permission matrix linking company, site, activity and authority.
Choose the product pathway
For human pharmaceuticals, DRAP lists Form 5F CTD routes and published second-edition guidance effective 10 March 2026. For medical devices, the standard pathway is Class A enlistment or Class B, C and D registration. Verify the classification, current amendments and any product-specific exception before filing.
- Output: Product pathway, submission checklist and evidence owner.
Check the November 2026 health-products update
DRAP notified the Alternative Medicines and Health Products Rules, 2026 on 16 November and announced its online licensing and registration system on 17 November. For existing provisional certificates or pending applications, consult the transition provisions and confirm any applicable filing requirements with DRAP.
- Output: Current form and portal plus a documented transition assessment where relevant.
Control labeling and lifecycle commitments
Align pack copy and promotion with the applicable claims and approved particulars. Plan for renewals, variations, complaints, vigilance, recalls and record retention according to the category and authorization.
- Output: Approved artwork and assigned lifecycle obligations.
Authoritative references
- DRAP — Pharmaceutical drugs and registration pathways
- DRAP — Form 5F CTD guidance, second edition
- DRAP — Medical Devices Rules, 2017, consolidated through April 2022
- DRAP — Medical device risk classification
- DRAP — Medical Devices Rules amendment, S.R.O. 1049(I)/2025
- DRAP — Alternative Medicines and Health Products Rules, 2026
- DRAP — Online licensing and registration for alternative medicines and health products
- DRAP — Quality assurance, GDP and cold-chain guidance
Related MHPL solution Regulatory & Market Access

Quality nucleus